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Abstract
Background: This study estimates life expectancy with and without type 2 diabetes for individuals in Lower
Saxony, Germany in order to detect a trend in population health.
Methods: Morbidity and mortality data derived from German administrative claims data (statutory health insurance,
AOK Niedersachsen, N = 2,900,065) were used covering 10 years from 2005 to 2014. Life table analysis was applied
for calculating life expectancy, life expectancy free of type 2 diabetes, life expectancy with type 2 diabetes, and the
proportion of life expectancy free of diabetes to total life expectancy using the Sullivan method.
Results: The total life expectancy increase is stronger in men than in women: At the age of 20, total life expectancy
was 55.0 years in 2005 and 56.3 years in 2014 for men, whereas it was 61.7 years in 2005 and 62.5 years in 2014 for
women. Decreases in life expectancy without type 2 diabetes were more pronounced in women than in men.
Accordingly, life expectancy with type 2 diabetes increased in both women and in men. The proportion of life
expectancy without diabetes to total life expectancy decreased, indicating a similar development in both. For
example, at the age of 60, the proportion of life expectancy without diabetes to total life expectancy decreased
from 0.75 in 2005 to 0.66 in 2014 for men, while it decreased from 0.77 in 2005 to 0.70 in 2014 for women.
Conclusions: Against the background of increasing total life expectancy, the time spent in morbidity increased for
the case of type 2 diabetes in Lower Saxony, Germany.
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Background
Population aging leads to an increase in chronic diseases,
with type 2 diabetes being one of the most relevant issues
[1]. From 1980 to 2014, the global prevalence of diabetes
in adults almost doubled because of an increase in type 2
diabetes [2]. Tamayo and colleagues [3] estimated the
number of Europeans with diabetes between 20 and
79 years to be 56 million in 2013. This estimate corre-
sponds to a raw overall prevalence of 8.5% and an age-
standardized prevalence of 6.8%. An increase of nearly 10
million people with diabetes is predicted for 2035.
As life expectancy is increasing [4], whether the
additional life year gains are spent in good or in poor
health must be examined. Three hypotheses have been
formulated to outline the ways morbidity might develop.
Fries [5] assumed that the onset of impairment and mor-
bidity would be postponed to a higher age, which might
proceed at a faster pace than the increase of life expect-
ancy, therefore leading to shorter time periods spent in
poor health. Fries called this concept compression of
morbidity and attributed it to successful primary preven-
tion and improved living conditions. A different hypoth-
esis was proposed by Gruenberg [6], who assumed that
medical progress prolongs life with chronic diseases, thus
leading to morbidity expansion. Finally, Manton [7] com-
bined both perspectives by assuming that, even with in-
creases in life expectancy, the relative number of life years
spent in good and poor health may remain unchanged,
and that, due to medical progress, the quality of life would
be improved. Manton called this a dynamic equilibrium.
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As longitudinal data are rare, few studies on these
concepts have been conducted thus far. Depending on the
country, the data, and the outcomes measured, findings
on changing morbidity patterns vary but point in the same
direction for type 2 diabetes. Prevalence is reported to
increase [1, 2], and onset age is shifted into younger age
groups, mainly due to obesity in childhood and adoles-
cence [8–11]. The corresponding development of morbid-
ity with type 2 diabetes may thus be described as
expansion. Furthermore, Loukine and colleagues [12]
reported a lower total life expectancy and a lower health-
adjusted life expectancy in patients with type 2 diabetes
than in individuals without the chronic condition.
Tancredi and colleagues [13] analyzed Swedish registry
data and found higher mortality in type 2 diabetes patients
than in the general population.
The use of registry or claims data alone or in combination
with other data sources is growing in diabetes research [14]:
based on the data of several German health insurance pro-
viders, Hoffmann and Icks [15] reported an overall preva-
lence of diabetes of 6.9% in individuals between 18 and
79 years. However, regional differences in Germany have to
be considered: reported age-standardized incidence rates of
type 2 diabetes ranged from 0.9% to 1.7% [16]. Due to the
heterogeneous results, more research on the development
of type 2 diabetes is needed. Many studies covered a limited
age span or were based on low case numbers. The aim of
our study was to investigate the development of life expect-
ancy free of type 2 diabetes and life expectancy with type 2
diabetes over time by using a large claims database covering
10 years. Whether life expectancy with type 2 diabetes in-
creased over a longer observation period requires examin-
ation. Our hypothesis was that life expectancy with type 2
diabetes may increase over time. Compression of morbidity
would be present if total and life expectancy free of type 2
diabetes had increased, and if life expectancy with type 2
diabetes had decreased in relative terms.
To our knowledge, this is the first German study using
health insurance data for estimating life expectancy free
of type 2 diabetes and life expectancy with type 2
diabetes. The advantage to using this database is its
completeness. All diagnosed cases of the insurance
population are included, and data are also available if
subjects were temporarily or permanently unable or
reluctant to respond.
In Germany, a national disease management program
for type 2 diabetes was introduced in 2002 within the
framework of the German Social Code, Book V (SGB V)
[17, 18]. This program is available for all patients with
statutory health insurance, which applies to the vast
majority of the population. The disease management
program defines a quality assured course of treatment
reflecting the current national clinical guidelines for the
treatment of type 2 diabetes.
Methods
Data
The database consists of anonymized statutory health
insurance claims data from Lower Saxony, Germany
(Allgemeine Ortskrankenkasse Niedersachsen). For the
years 2005 to 2014, data for N = 2,900,065 insured are avail-
able, and for each year, approximately two million women
and men with a balanced gender ratio are included. Origin-
ally, the data were collected for accounting purposes. They
contain demographic variables, inpatient and outpatient
diagnoses (coded according to ICD-10), as well as out-
patient medications coded according to ATC [19]. The
lower age limit for inclusion is 18 years. As health insurance
providers maintain their records only for a limited time
period, data are available for 2005 to 2014 only.
Statistical analyses
Age-standardized prevalence and mortality rates were
calculated for all calendar years. A comparison between
the different years is possible by keeping the age struc-
ture constant over time. This was achieved by using the
age distributions of men and women in 2009 as the
standard population.
Total life expectancy, life expectancy free of type 2 dia-
betes, life expectancy with type 2 diabetes, and the propor-
tion of life expectancy without diabetes to total life
expectancy were estimated. First, we applied a period life
table analysis based on our dataset to calculate the total life
expectancy [20]. This is the basis for the Sullivan method
[21] that we applied next, and which is often used in demo-
graphic analyses to assess the health status of a population.
The Sullivan method combines information on morbidity
and mortality to estimate years lived without and with a
specific disease. In our case, age-specific type 2 diabetes
prevalence rates were linked to the period life table. The
Sullivan method enables the division of total life expect-
ancy into life expectancy without type 2 diabetes and life
expectancy with type 2 diabetes. Thus, the expected aver-
age life years without and with type 2 diabetes at a specific
age can be determined. Additionally, the proportion of life
expectancy without diabetes to total life expectancy was
computed with this method, depicting the relative amount
of expected healthy years compared to total life expectancy
for each year of age. We generated period life tables for
each year from 2005 to 2014 separately for men and
women in order to obtain the total life expectancy. As the
data were available from age 18, the life table began at this
age and ended with the final age group of 100+. We used
the unabridged life table because data were available for
each single year of age. The claims data contain informa-
tion on the year of birth and the year of death as well as
the duration of insurance period. Based on the number of
days an individual was insured in a respective year, the
mid-year population was calculated. Age-specific mortality
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rates were obtained by dividing the total deaths by the
mid-year population for every single age. There is no infor-
mation on the cause of death. Age-specific type 2 diabetes
prevalence rates were calculated in the same way. The dif-
ferent life expectancies were displayed starting from age 20
in 10-year intervals up to 80 years.
Classification of type 2 diabetes cases
The identification of individuals with type 2 diabetes
from health insurance data is methodologically challen-
ging. Due to the occurrence of coding errors, different
diabetes diagnoses might appear for one individual over
the entire insurance period. However, we can limit the
error because 80 to 90% of all diabetes cases can be
attributed to type 2 [22].
Our goal was to minimize this source of error. Therefore,
type 2 diabetes patients were selected by applying a step-
wise procedure: outpatient and inpatient physician diagno-
sis codes according to ICD-10 are available quarterly. We
classified individuals as having type 2 diabetes if they pre-
dominantly received ICD-10 E11 diagnoses (out of all
appearing diabetes diagnoses) in their insurance period. We
decided to include men and women who most frequently
had the unspecific diagnosis ICD-10 E14, as the majority of
diabetes patients have type 2. Furthermore, prescribed
diabetes medications coded according to the ATC-
classification were available. This enabled the identification
of individuals receiving oral antidiabetics (ATC-A10B) or
insulin (ATC-A10A). As not all type 2 diabetes patients are
treated with medication, this could not be the only method
for validation. If men or women predominantly had type 1
diabetes diagnoses (among other diabetes diagnoses), but
did not have an insulin prescription in the entire insurance
period, we classified them as implausible cases of type 1
diabetes. Therefore, they were assigned to the group of type
2 diabetes patients. Individuals with a diabetes diagnosis in
only one quarter without any medication appearing in the
entire insurance period but who were insured for longer
than one quarter were defined as implausible cases and
therefore excluded. Gaps without a diabetes diagnosis could
appear in one individual over the insurance period between
2005 and 2014. In these cases, we still classified the individ-
ual as having type 2 diabetes because the disease is chronic.
Data management and the analyses were performed in
Stata 11MP [23] and R [24].
Results
Prevalence
Age-standardized prevalence rates of type 2 diabetes in-
creased from 2005 to 2014 (Table 1). However, they were
generally higher in women than in men. Age-standardized
prevalence rates in men rose from 10.7% in 2005 to 14.5%
in 2014. In women, the rate was 12.0% in 2005 and 15.8%
in 2014. The total number of insured individuals as well as
the number of deaths remained similar in women, but in
men, the number of deaths increased somewhat over the
ten-year period. Age-standardized mortality rates declined
slightly over the observation period in women and in men.
Total life expectancy
Total life expectancy increased slightly from 2005 to
2014 in women and in men (Table 2). For example, the
total life expectancy of women at the age of 20
amounted to 61.7 years in 2005 and 62.5 years in 2014.
In men at the age of 20, the total life expectancy was
55.0 years in 2005 and 56.3 years in 2014. At age 80,
men were expected to live 7.0 years in 2005 and 7.6 years
in 2014. Women at age 80 had a total life expectancy of
8.8 years in 2005 and 9.5 years in 2014. Regardless of the
selected age or year, women always showed higher
values than men. Comparing 2014 to 2005, the increases
were significant for all ages and both sexes.
Life expectancy without type 2 diabetes
Life expectancy without type 2 diabetes decreased con-
tinuously in women and in men but was more pro-
nounced in women (Table 3). Analogously to total life
expectancy, female life expectancy without type 2 diabetes
was higher than that of males. For example, in males, life
expectancy without type 2 diabetes at age 60 was 14.4 years
in 2005 and 13.1 years in 2014, whereas it amounted to
18.5 years in 2005 and 17.2 years in 2014 for women at
age 60. Again, regardless of the selected age or year,
women were always expected to live more years without
type 2 diabetes than men. The decreases were significant
for all ages and both sexes when comparing 2014 to 2005.
Life expectancy with type 2 diabetes
Life expectancy with type 2 diabetes increased steadily
over the observation period from 2005 to 2014 (Table 4).
In agreement with the previous findings, life expectancy
with type 2 diabetes was higher in women. The develop-
ment of life expectancies with type 2 diabetes was almost
similar for ages 20 to 40, although changes could be ob-
served from the age of 50 onwards. For instance, men at
the age of 50 were expected to spend 5.4 years of their
remaining total life expectancy with type 2 diabetes in
2005 and 7.6 years in 2014. Women at age 50 had a life
expectancy with type 2 diabetes of 6.3 years in 2005 and
8.3 years in 2014. For all ages and both sexes, the increases
when comparing 2014 to 2005 were significant.
Proportion of life expectancy without diabetes to total
life expectancy
Overall, a continuous decline in the proportion of life ex-
pectancy without diabetes to total life expectancy was vis-
ible in both sexes with increasing age but also over the 10-
year period (Table 5). In contrast to the aforementioned
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findings, the relative examination of years without type 2
diabetes and total life expectancy revealed a similar devel-
opment for men and women, because the figures were not
substantially different. This means that the relative
amount of years without type 2 diabetes to total life ex-
pectancy was almost the same for men and women at
every selected age or year. Stronger decreases over the ob-
served time period were visible in the older age groups
after the age of 50. At the age of 20, the proportion of life
expectancy without diabetes to total life expectancy of
men was 0.90 in 2005 and dropped slightly to 0.86 in
2014, whereas in women, it was 0.89 in 2005 and 0.86 in
2014. In both sexes, the proportion of life expectancy
without diabetes to total life expectancy amounted to 0.73
for age 70 in 2005 and decreased to 0.61 in men and 0.65
in women in 2014. When comparing 2014 to 2005, the de-
creases were significant for all ages and both sexes.
Discussion
The objective of our study was to examine life expect-
ancy without type 2 diabetes and life expectancy with
type 2 diabetes. We used German administrative claims
data and examined the development of different life
expectancies over a period of 10 years. The total life ex-
pectancy was noted to be increasing slightly. While this
finding applies more to men than to women, it should
be kept in mind that the female total life expectancy of
the population under study was already higher than in
males. The reduction of life expectancy without type 2
diabetes was more pronounced in women than in men.
However, life expectancy with type 2 diabetes increased
in both, and the proportion of life expectancy free of
diabetes to total life expectancy decreased in men and
women, thus indicating that the relative amount of type
2 diabetes free life years decreased over the observation
period. Therefore, our hypothesis that life expectancy
with type 2 diabetes increases was confirmed for both
sexes, and it can be concluded that an expansion of
morbidity has occurred.
The increase in age-standardized prevalence rates as
well as in life expectancy with type 2 diabetes is in ac-
cordance with reported increases in prevalence and with
the rising number of younger patients with type 2 dia-
betes [8–10]. High obesity rates in German children and
young adults might play an important role in the early
development of the disease [25, 26]. Lifestyle changes,
Table 1 Type 2 diabetes cases, age-standardized prevalence rates of type 2 diabetesa, number of deaths, age-standardized mortality
ratesa and number of all insured (N) by year and sex
Year Type 2 diabetes cases Age-standardized prevalence




Men 2005 89 121 10.7% 14 404 1.8% 900 551
2006 97 107 11.7% 14 360 1.8% 894 701
2007 102 279 12.3% 14 254 1.8% 888 370
2008 107 113 12.9% 14 512 1.8% 874 690
2009 110 682 13.3% 14 618 1.8% 875 488
2010 127 553 13.8% 15 645 1.7% 1 012 304
2011 132 124 13.8% 15 954 1.7% 1 020 440
2012 134 949 14.0% 16 208 1.6% 1 025 982
2013 135 129 14.0% 16 781 1.7% 1 026 358
2014 140 232 14.5% 16 345 1.6% 1 032 109
Total 1 176 289 153 081 9 550 993
Women 2005 119 074 12.0% 19 376 2.0% 1 041 281
2006 126 766 12.9% 18 645 1.9% 1 030 198
2007 131 660 13.5% 18 454 1.9% 1 018 332
2008 136 148 14.1% 18 717 1.9% 999 761
2009 138 651 14.5% 18 570 1.9% 993 029
2010 152 752 15.0% 19 374 1.9% 1 103 039
2011 156 454 15.1% 18 897 1.8% 1 104 183
2012 158 531 15.3% 19 255 1.9% 1 102 032
2013 157 316 15.4% 19 806 1.9% 1 094 618
2014 161 701 15.8% 18 614 1.8% 1 092 462
Total 1 439 053 189 708 10 578 935
aStandard population AOK NDS 2009
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especially of diet and exercise, have been demonstrated
to be influential on the long-term development of type 2
diabetes [27]. Our study illustrates the importance of
preventive action towards reducing obesity, especially in
childhood, in order to avoid type 2 diabetes-related com-
plications and premature mortality.
The relative amount of life years without type 2 diabetes
decreased, as indicated by the proportion of life expect-
ancy without diabetes to total life expectancy, thus raising
concern about the future development. Our results are in
line with projections for Australia and Mexico that indi-
cate an increase in diabetes prevalence and lifetime risk of
developing the disease [28, 29]. If this trend persists, it can
be assumed that disease-related complications and health
care costs will increase accordingly. For example, Wong et
al. [30] discovered higher complication and mortality rates
in patients with a young onset age of type 2 diabetes. Bar-
denheier et al. [31] found higher disability and mortality
rates in men and women with diabetes than in the group
without the disease. Based on a prediction for Germany,
the health costs of type 2 diabetes are estimated to in-
crease by 79% from 11.8 billion euro in 2010 to 21.1 bil-
lion euro in 2040 if the therapeutic procedures remain
unchanged [32]. Furthermore, the slight decrease in mor-
tality found in our data could also be responsible for the
increase in life expectancy with type 2 diabetes. This find-
ing is in line with previous studies from Denmark [33]
and the United States [34] that show a higher lifetime risk
of type 2 diabetes due to increasing diabetes incidence
and declining mortality.
It can be discussed whether earlier onset of type 2
diabetes may be due to improved diagnostics and earlier
detection, or whether onset has actually shifted towards
younger age groups. In both cases, a population would
appear increasingly morbid. As diagnostic procedures
have not changed since disease management programs
(DMP) were introduced in 2002 in Germany [17], the
observed changes might be attributed to an earlier onset
age. It is also conceivable that earlier detection and
better therapies might prevent late complications and
thus improve the quality of life of patients. Accordingly,
disease courses may be less severe, and health costs may
decrease. To decide between these alternatives, future
studies should also include subjective information on
the quality of life of patients with type 2 diabetes. Then,
a distinction between a mere expansion of morbidity
and the dynamic equilibrium as an alternative pattern
would be possible. Even in the case of prolonged
morbidity periods, improvements of quality of life in
type 2 diabetes patients would point towards a dynamic
equilibrium. Instead of quality of life measures as an in-
dicator of disease severity, one might also consider the
occurrence of diabetes-related complications, especially
when using claims data sources.
The observation period from 2005 to 2014 may be
viewed as rather short, but it has to be kept in mind that
changes in the development of morbidity and mortality
are constant and consistently moving in the same direc-
tion. The advantages of the claims dataset are the broad
age range and the large number of individuals, which
made it possible to apply period life tables. Furthermore,
an advantage of the administrative nature of health insur-
ance data is the absence of selection and response bias.
For all insured individuals, complete health care informa-
tion is available, even for those with deteriorating health
status who are more likely to be non-respondents in
surveys [35, 36]. The distributions of age, gender, and em-
ployment rates in our data were similar to the population
of Lower Saxony and Germany. However, the qualification
level of the insurance population was lower [37].
Conclusions
We found an increase in total life expectancy but also of
life expectancy with type 2 diabetes between 2005 and
2014. These findings indicate an expansion of morbidity.
This finding highlights the importance of preventive
measures to avoid the deterioration of population heath
in terms of more disease-related complications and in-
creasing health care costs. However, possible improve-
ments of therapies and quality of life in type 2 diabetes
patients should be subject to future analyses in order to
determine whether a dynamic equilibrium is present ra-
ther than a morbidity expansion.
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